Literature DB >> 28694

Piperacillin: in vitro evaluation.

G P Bodey, B Le Blanc.   

Abstract

The in vitro activity of a new semisynthetic penicillin, piperacillin, was determined against 577 clinical isolates of gram-positive cocci and gram-negative bacilli. A concentration of 12.5 mug/ml inhibited 92% of isolates of Pseudomonas aeruginosa, 82% of Serratia marcescens, 73% of Escherichia coli, 61% of Klebsiella spp., and 42% of Enterobacter spp. Most Proteus spp. were extremely susceptible; over 85% were inhibited by 0.10 mug/ml. Piperacillin failed to inhibit the growth of gram-negative bacilli when large inocula were used. The type of media and pH had variable effects on the activity of piperacillin, depending upon the organism. Piperacillin was generally less active than PC-904 against gram-negative bacilli, but was consistently more active than carbenicillin and ticarcillin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 28694      PMCID: PMC352408          DOI: 10.1128/AAC.14.1.78

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Infections in cancer patients. Results with gentamicin sulfate therapy.

Authors:  G P Bodey; E Middleman; T Umsawadi; V Rodriguez
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

2.  Therapeutic trials with tobramycin.

Authors:  M Valdivieso; N Horikoshi; V Rodriguez; G P Bodey
Journal:  Am J Med Sci       Date:  1974-09       Impact factor: 2.378

3.  In vitro and in vivo antibacterial activity of T-1220, a new semisynthetic penicillin.

Authors:  K Ueo; Y Fukuoka; T Hayashi; T Yasuda; H Taki; M Tai; Y Watanabe; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

4.  New semi-synthetic penicillin active against Pseudomonas pyocyanea.

Authors:  P Acred; D M Brown; E T Knudsen; G N Rolinson; R Sutherland
Journal:  Nature       Date:  1967-07-01       Impact factor: 49.962

5.  Sequential hospitalwide outbreaks of resistant Serratia and Klebsiella infections.

Authors:  F E Thomas; R T Jackson; A Melly; R H Alford
Journal:  Arch Intern Med       Date:  1977-05

6.  Multidrug-resistant Proteus rettgeri: an emerging problem.

Authors:  P B Iannini; T C Eickhoff; F M LaForce
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

  6 in total
  20 in total

1.  Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity.

Authors:  S S Weaver; G P Bodey; B M LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

2.  Early synergistic interaction between semisynthetic penicillins and aminoglycosidic aminocyclitols against Enterobacteriaceae.

Authors:  R H Glew; R A Pavuk
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

3.  Evaluation of piperacillin sodium in the treatment of infections in immune compromised patients.

Authors:  D A Kelly; J J Fennelly
Journal:  Ir J Med Sci       Date:  1982-08       Impact factor: 1.568

4.  Comparative synergistic activity of ceftriaxone-piperacillin versus ceftriaxone-netilmicin.

Authors:  K Machka; R Dietz
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

5.  CI-867, a new semisynthetic penicillin: in vitro studies.

Authors:  S S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

6.  Penetration of piperacillin into bronchial mucosa and sputum.

Authors:  G E Marlin; K R Burgess; J Burgoyne; G R Funnell; M D Guinness
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

7.  In vitro activities of new beta-lactam antibiotics against Acinetobacter spp.

Authors:  I Garcia; V Fainstein; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  Comparative in vitro study of temocillin (BRL 17421), a new penicillin.

Authors:  R Bolivar; S S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

9.  Statistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

10.  Piperacillin plus vancomycin in the therapy of febrile episodes in cancer patients.

Authors:  L Jadeja; R Bolivar; V Fainstein; M Keating; K McCredie; M Hay; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.